As disruption of the IL6-JAK2-STAT-S100A8/S100A9 cascade impacts HER2+ cell viability, these data serve as the rationale for targeting this pathway in patients with HER2+ breast cancer. This evidence concerns the gene IL6 and breast carcinoma.